Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer - PubMed (original) (raw)
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer
Jianghua Wang et al. Cancer Res. 2006.
Abstract
Recent studies have reported that the majority of prostate cancers express fusion genes in which the 5' region of the androgen-regulated TMPRSS2 gene is fused to an ETS family transcription factor, most commonly the ERG gene. We have characterized in detail the expression of TMPRSS2/ERG fusion mRNAs and correlated the isoforms expressed and expression levels with clinical outcome in cancers from men undergoing radical prostatectomy. Overall, 59% of clinically localized prostate cancers express the TMPRSS2/ERG fusion gene, confirming the initial observations of high frequency expression of this fusion mRNA in prostate cancer. There was significant variation in the alternatively spliced isoforms expressed in different cancers. Expression of an isoform, in which the native ATG in exon 2 of the TMPRSS2 gene is in frame with exon 4 of the ERG gene, was associated with clinical and pathologic variables of aggressive disease. Expression of other isoforms, in which the native ERG ATG in exon 3 was the first in-frame ATG, was associated with seminal vesicle invasion, which is correlated with poor outcome following radical prostatectomy. Cancers not expressing these isoforms tended to express higher levels of fusion mRNAs, and in this group, higher expression levels of fusion mRNA were present in cancers with early prostate-specific antigen recurrence. Thus, both the isoforms of TMPRSS2/ERG fusions expressed and expression level may affect prostate cancer progression.
Similar articles
- Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J. Hermans KG, et al. Clin Cancer Res. 2009 Oct 15;15(20):6398-403. doi: 10.1158/1078-0432.CCR-09-1176. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825963 - Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, López-Guerrero JA. Rubio-Briones J, et al. J Urol. 2010 May;183(5):2054-61. doi: 10.1016/j.juro.2009.12.096. Epub 2010 Mar 19. J Urol. 2010. PMID: 20303538 - Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M, Lissbrant E, Damber JE, Stenman G. Winnes M, et al. Oncol Rep. 2007 May;17(5):1033-6. Oncol Rep. 2007. PMID: 17390040 - ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. Tomlins SA, et al. Eur Urol. 2009 Aug;56(2):275-86. doi: 10.1016/j.eururo.2009.04.036. Epub 2009 Apr 24. Eur Urol. 2009. PMID: 19409690 Review.
Cited by
- Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study.
Ma C, Wang X, Dai JY, Turman C, Kraft P, Stopsack KH, Loda M, Pettersson A, Mucci LA, Stanford JL, Penney KL. Ma C, et al. Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1436-1443. doi: 10.1158/1055-9965.EPI-23-0275. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37555839 Free PMC article. - Fusion sequencing via terminator-assisted synthesis (FTAS-seq) identifies TMPRSS2 fusion partners in prostate cancer.
Drazdauskienė U, Kapustina Ž, Medžiūnė J, Dubovskaja V, Sabaliauskaitė R, Jarmalaitė S, Lubys A. Drazdauskienė U, et al. Mol Oncol. 2023 Jun;17(6):993-1006. doi: 10.1002/1878-0261.13428. Epub 2023 Apr 13. Mol Oncol. 2023. PMID: 37300660 Free PMC article. - Early Cell Cultures from Prostate Cancer Tissue Express Tissue Specific Epithelial and Cancer Markers.
Ryabov VM, Baryshev MM, Voskresenskiy MA, Popov BV. Ryabov VM, et al. Int J Mol Sci. 2023 Feb 1;24(3):2830. doi: 10.3390/ijms24032830. Int J Mol Sci. 2023. PMID: 36769153 Free PMC article. - Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer.
Wang Q, Chen J, Singh S, Xie Z, Qin F, Shi X, Cornelison R, Li H, Huang H. Wang Q, et al. Cell Biosci. 2022 Sep 10;12(1):153. doi: 10.1186/s13578-022-00893-5. Cell Biosci. 2022. PMID: 36088396 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical